Evidence map›Paper›PMID 29274033›Full record

ArticleEuropean journal of nutrition2019

Supplementation with an insoluble fiber obtained from carob pod (Ceratonia siliqua L.) rich in polyphenols prevents dyslipidemia in rabbits through SIRT1/PGC-1α pathway.

María Valero-Muñoz, Sandra Ballesteros, Baltasar Ruiz-Roso, Lourdes Pérez-Olleros, Beatriz Martín-Fernández, Vicente Lahera, Natalia de Las Heras

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nutrition, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Carob (Reviews on recent clinical trials · 2024
    Pooled it
  2. Article
  3. Review
  4. Carob Extract (Pharmaceutics · 2023
    Article
  5. Antioxidants (Basel, Switzerland) · 2023
    Article
  6. Evaluation of The Effects of Carob (Journal of clinical research in pediatric endocrinology · 2023
    Article
  7. Article
  8. Review
  9. Lipid-Lowering Effects of Carob Extracts (Frontiers in pharmacology · 2022
    Article
  10. Supplementation with a Carob (Antioxidants (Basel, Switzerland) · 2020
    Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

María Valero-MuñozDepartment of Physiology, School of Medicine, Universidad Complutense, 28040, Madrid, Spain.
Sandra BallesterosDepartment of Physiology, School of Medicine, Universidad Complutense, 28040, Madrid, Spain.
Baltasar Ruiz-RosoDepartment of Nutrition and Food Sciences I, School of Pharmacy, Universidad Complutense, Madrid, Spain.
Lourdes Pérez-OllerosDepartment of Nutrition and Food Sciences I, School of Pharmacy, Universidad Complutense, Madrid, Spain.
Beatriz Martín-FernándezDepartment of Physiology, School of Medicine, Universidad Complutense, 28040, Madrid, Spain.
Vicente LaheraDepartment of Physiology, School of Medicine, Universidad Complutense, 28040, Madrid, Spain.
Natalia de Las HerasDepartment of Physiology, School of Medicine, Universidad Complutense, 28040, Madrid, Spain. nlashera@ucm.es.
Universidad Complutense de Madrid · ES

Funding

Comisión Interministerial de Ciencia y Tecnología SAF2011-30396Ministerio de Ciencia e Innovación IPT-2012-0213-060000
6 · The paper itself

Abstract

purposeTo investigate the mechanism implicated in the effect of an insoluble fiber (obtained from carob pod) rich in polyphenols (IFCP) in lipid metabolism in the liver.

methodsMale New Zealand rabbits were fed with the following diets for 8 weeks: control diet (CT group), dyslipidemic diet supplemented with 0.5% cholesterol + 14% coconut oil (DL group) and dyslipidemic diet containing 0.5% cholesterol + 14% coconut oil plus 3% IFCP (DL + IFCP group).

resultsDyslipidemic diet with IFCP was able to reduce development of mixed dyslipidemia, liver relative weight and collagen I protein expression compared to DL rabbits. Analyses of the main enzymes implicated in cholesterol and triglycerides metabolism revealed that IFCP increased hepatic concentration of 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CoA reductase) and cytochrome P450, family 7, subfamily a, polypeptide 1C (CYP7A1) (82.34, 114.42%, respectively) as well as protein expression of LDL receptor (42.48%) in DL rabbits. Importantly, IFCP also increased hepatic lipase (HL) levels (91.43%) and decreased glycerol phosphate acyltransferase (GPAT) and sterol regulatory element-binding protein 1C (SREBP1c) liver expression levels (20.38 and 41.20%, respectively). Finally, sirtuin 1 (SIRT1) and peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1α) hepatic expression increased in DL + IFCP group compared with DL (159.81 and 48.00%, respectively).

conclusionsThese findings show that IFCP is able to abrogate the deleterious effects of hepatic dyslipidemia by modulating SIRT1 and PGC-1α pathways.

Indexed as

AnimalsDietary FiberDyslipidemiasGalactansLipid MetabolismLiverMaleMannansPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaPlant GumsPolyphenolsRabbitsSirtuin 1Dietary FiberGalactanslocust bean gumMannansPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaPlant GumsPolyphenolsSirtuin 1DyslipidemiaInsoluble fiber from carob podPGC-1αPolyphenolsSIRT1

Identifiers

PMID29274033
OpenAlexW2781255304

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.